Skip to main content
padlock icon - secure page this page is secure

Evaluation of miLINC to shorten time to treatment for rifampicin-resistant Mycobacterium tuberculosis

Buy Article:

$23.62 + tax (Refund Policy)

BACKGROUND: Achieving the 90–90–90 targets for tuberculosis (TB) will require interventions that enhance diagnosis, linkage, treatment and adherence to care. As a first step in the process, our team designed a suite of smartphone applications known as miLINC to improve time from diagnosis to treatment initiation in drug-resistant TB patients.

SETTING: Three clinical locations in a large, peri-urban district in KwaZulu-Natal, South Africa.

OBJECTIVE: To assess the acceptability, feasibility and impact of the miLINC mobile health applications as a solution to reducing the time from presentation to treatment initiation of rifampicin-resistant (RR) TB patients.

METHODS: We used a prospective, observational quality improvement evaluation of miLINC's impact among newly diagnosed patients with RR-TB.

RESULTS: A convenience sample comprising details of 6341 patients with presumptive TB were entered into miLINC. Of the 631 TB-positive sputum specimens, 41 (6.5%) were found to be RR-TB. The mean time from clinical presentation to RR-TB treatment initiation was 3 days, 21 h, 17 min.

CONCLUSION: This is the first study to suggest that the time from presentation to diagnosis and to treatment initiation for patients with RR-TB can be significantly improved using an integrated approach combining technology with appropriate human resources.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: South Africa; linkage to care; mhealth; treatment initiation; tuberculosis

Document Type: Research Article

Affiliations: 1: REACH Initiative, Johns Hopkins University School of Nursing, Baltimore, MD, Department of Community Public Health, Johns Hopkins University School of Nursing, Baltimore, MD 2: Johns Hopkins Center for Clinical Global Health Education, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA 3: National Health Laboratory Service, National Priority Programs Unit, Johannesburg 4: South African National Department of Health, Pretoria 5: National Health Laboratory Service, National Priority Programs Unit, Johannesburg, University of the Witwatersrand, School of Clinical Medicine, Johannesburg, South Africa

Publication date: September 1, 2019

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more